an insight into the management of cytopenias in mf
Published 2 years ago • 157 plays • Length 4:48Download video MP4
Download video MP3
Similar videos
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
1:28
momelotinib in 2024: how should this agent be used in mf with anemia?
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
-
2:03
unmet needs in immune thrombocytopenia
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
1:31
risk-adjusted safety analysis of pacritinib for patients with mf
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
58:04
complement testing in the diagnosis and management of thrombotic microangiopathy
-
1:10:58
developing methods for comparability studies of therapeutic monoclonal antibodies
-
3:38
looking to the future in the treatment of beta thalassemia
-
1:26
updates on the use of momelotinib for the treatment of mf & clinical trials evaluating this agent
-
1:46
how would the approval of luspatercept benefit the treatment landscape in myelofibrosis
-
0:39
promising therapeutic options emerging in hemophilia
-
2:09
advances in the management of fit adults with aml
-
3:17
estimating transfusion-related medical costs & time burden in patients with mf in simplify-1
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
3:29
current approaches and new approvals in mf and pv
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:57
enhancing clinical care in lr-mds: managing symptomatic/transfusion-dependent anemia
-
0:57
potential approval of quizartinib in aml & its place in the aml treatment regimen
-
0:55
adaptive licensing: a new approach for authorizing medicines